Showing results (221-230 of 285) with videos related to

Sort By:
Pageof 29
Lancet (London, England)|June 8, 2014
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMichael Manns, Patrick Marcellin, Fred Poordad, et al.
Lancet (London, England)|December 14, 2012
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyPatrick Marcellin, Edward Gane, Maria Buti, et al.
Journal of Hepatology|July 22, 2014
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumaratePatrick Marcellin, Maria Buti, Zahari Krastev, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 21, 2017
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral TherapyIra M Jacobson, Mary K Washington, Maria Buti, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
JHEP Reports : Innovation in Hepatology|March 17, 2022
Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis BNicholas van Buuren, Ricardo Ramirez, Cameron Soulette, et al.
Hepatology (Baltimore, Md.)|May 24, 2012
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirinIra M Jacobson, Patrick Marcellin, Stefan Zeuzem, et al.
Plos One|December 17, 2015
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC StudyFrédégonde About, Tiphaine Oudot-Mellakh, Jonathan Niay, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Annals of Internal Medicine|October 3, 2007
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trialHenry L Y Chan, E Jenny Heathcote, Patrick Marcellin, et al.
Pageof 29